Skip to main content

Quantum Biopharma Ltd.

corporate_fare Company Profile

Quantum Biopharma Ltd.

QNTM·NASDAQ·Life Sciences·CIK 0001771885

Quantum Biopharma Ltd. is a biopharmaceutical company that operates through two segments: Biopharmaceutical Innovation and Strategic Investments. The company focuses on researching and developing a portfolio of assets and biotech solutions for neurodegenerative, inflammatory, metabolic, and alcohol misuse disorders, with drug candidates at various development stages. Its lead compound, Lucid-MS, is a patented new chemical entity currently in a Phase 2 clinical trial. Lucid-MS aims to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, as demonstrated in preclinical models. Quantum Biopharma Ltd. also develops FSD-PEA, which is preparing for a Phase 2 trial for inflammatory diseases like mast cell activation syndrome. Other developments include Lucid-PSYCH for major depressive disorder and unbuzzd, a dietary supplement for alcohol misuse. The Strategic Investments segment includes a portfolio of loans secured by residential property. The company, founded in 1998, changed its name from FSD Pharma Inc. to Quantum Biopharma Ltd. in August 2024 and is based in Toronto, Canada.

Quantum Biopharma Ltd. (NASDAQ:QNTM) is a publicly traded company in the Life Sciences sector. Wiseek monitors QNTM SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • FDA Places Lead MS Drug (Lucid-MS) IND on Clinical Hold, Halting Development
  • Quantum Biopharma Engages Stocks.news for Investor Relations and Marketing
  • Quantum BioPharma's MS Imaging Study with MGH Hits Midpoint, Showing Promising Early Data
  • Quantum Biopharma Boosts Liquidity, Files IND for MS Drug Phase 2 Trial, Extends Runway to 2027
  • Quantum Biopharma Secures $9.7M in Dilutive Financing Amidst Rising Losses and Negative Equity

Insider Transactions

QNTM files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with Q →
$3.83
52-week range · as of 2026-06-02 $2.07 – $38.25
Market cap
$24.51M
Volume
118.3K (0.3× avg)
3-mo avg 410.9K
Live data · 2026-06-14 03:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed QNTM - Latest Insights

QNTM
Jun 02, 2026, 11:50 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $4.97
Real-time Price: $3.83 info
Change: -$1.14 (-23%) info
Market Cap: $24.507M info
QNTM
Jun 02, 2026, 7:40 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.25
Real-time Price: $3.83 info
Change: -$1.42 (-27%) info
Market Cap: $24.507M info
QNTM
May 18, 2026, 3:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $6.71
Real-time Price: $3.83 info
Change: -$2.88 (-43%) info
Market Cap: $24.507M info
QNTM
May 07, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $5.11
Real-time Price: $3.83 info
Change: -$1.28 (-25%) info
Market Cap: $24.507M info
QNTM
May 06, 2026, 4:14 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $5.28
Real-time Price: $3.83 info
Change: -$1.45 (-27%) info
Market Cap: $24.507M info
QNTM
Apr 22, 2026, 9:31 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.59
Real-time Price: $3.83 info
Change: +$0.2384 (+7%) info
Market Cap: $24.507M info
QNTM
Apr 02, 2026, 8:30 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $4.40
Real-time Price: $3.83 info
Change: -$0.570 (-13%) info
Market Cap: $24.507M info
QNTM
Apr 01, 2026, 8:02 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $5.18
Real-time Price: $3.83 info
Change: -$1.35 (-26%) info
Market Cap: $24.507M info
QNTM
Mar 30, 2026, 7:50 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $5.09
Real-time Price: $3.83 info
Change: -$1.26 (-25%) info
Market Cap: $24.507M info
QNTM
Mar 30, 2026, 7:50 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $5.10
Real-time Price: $3.83 info
Change: -$1.27 (-25%) info
Market Cap: $24.507M info
QNTM
Mar 27, 2026, 8:10 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.79
Real-time Price: $3.83 info
Change: +$0.040 (+1%) info
Market Cap: $24.507M info
QNTM
Mar 27, 2026, 8:10 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.79
Real-time Price: $3.83 info
Change: +$0.040 (+1%) info
Market Cap: $24.507M info
QNTM
Mar 26, 2026, 4:02 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $3.83
Real-time Price: $3.83 info
Change: $0 (0%) info
Market Cap: $24.507M info
QNTM
Mar 26, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.40
Real-time Price: $3.83 info
Change: -$0.570 (-13%) info
Market Cap: $24.507M info
QNTM
Mar 23, 2026, 8:24 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $2.30
Real-time Price: $3.83 info
Change: +$1.53 (+67%) info
Market Cap: $24.507M info
QNTM
Mar 20, 2026, 7:35 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.28
Real-time Price: $3.83 info
Change: +$1.55 (+68%) info
Market Cap: $24.507M info